Cerebral vasospasm is a common postoperative complication in patients with cerebral aneurysms treated by endovascular embolization. This paper analyzes the clinical effect of fasudil combined with nimodipine in the prevention of this complication.
Total 80 patients with cerebral aneurysms who received endovascular embolization in Dushanzi People's hospital from January 1, 2019 to December 31, 2020 were randomly divided into control group and observation group, with 40 patients in each group. All patients were treated with nimodipine, and the observation group was treated with fasudil combined with nimodipine. The treatment effects of the two groups were compared.
The total effective rates of the observation group were higher than that of control group (97.50% vs 80.00%, P<0.05). The modified Rankin scale (mRS) of observation group was significantly lower than that of control group [(0.90±0.15) vs (2.80±0.28), P<0.05]. The Glasgow Coma Scale (GCS) and Barthel score of observation group were significantly higher than those of control group [(14.49±0.80) vs (10.98±0.65), P<0.05], [(79.97±4.44) vs (55.82±3.35), P<0.05]. The mean blood flow of posterior cerebral artery (PCA) and middle cerebral artery (MCA) of observation group were significantly lower than those of control group [(38.41±1.76) vs (45.54±2.99) cm/s, P<0.05], [(81.44±2.24) vs (92.33±4.43)cm/s, P<0.05]. Matrix metalloprotein-9 (MMP-9) and nuclear factor kappa-B (NF-κB) of observation group were significantly lower than those of control group [(133.33±8.88) vs (165.44±10.55)nmol/L, P<0.05], [(0.12±0.01) vs (0.25±0.03)nmol/L, P<0.05]. There was no significant difference in the incidence of adverse reactions after treatment between the two groups P>0.05.
Fasudil combined with nimodipine in the treatment of cerebral aneurysms patients after intravascular interventional embolization can effectively reduce the risk of postoperative cerebral vasospasm, reduce arterial blood flow velocity and coma index, effectively improve neurological function, and control the level of serum inflammatory factors, with significant effect and high safety.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |